Journal of Child Neurology · 2006 · 34 citations · 7 references
MedicineNeurologyPediatricsPediatric Clinical PharmacologyPediatric NeurologyPediatric TherapeuticsAcute Ischemic StrokeAcute Stroke ManagementCerebrovascular DiseasePediatric StrokeStrokeThrombolytic TherapyAcute Ischemic Stroke InterventionAcute Ischemic Stroke ManagementAcute Ischemic Stroke TreatmentClinical Outcome MeasurementDouble-blind TrialsIntravenous Tissue Plasminogen ActivatorPlasminogen ActivatorsThrombolysis In Ischemic Stroke
Intravenous tissue plasminogen activator is the only therapy approved by the US Food and Drug Administration (FDA) for the treatment of acute ischemic strokes. The National Institutes of Health (NIH)-sponsored study that led to the approval of tissue plasminogen activator to be used in acute ischemic strokes included only individuals 18 years of age and older. We report a case of a pediatric patient who suffered a dominant-hemisphere acute ischemic stroke who was treated with intravenous tissue plasminogen activator. Our patient's symptoms began to resolve 4 hours after treatment, and he had a complete recovery after 8 hours. The clinical outcome was excellent and without complications. Tissue plasminogen activator administration can be safe and effective in younger patients. Randomized, controlled, double-blind studies are needed.
7
Guidelines for the Early Management of Patients With Ischemic Stroke
Harold P. Adams, Robert J. Adams, Thomas Brott et al. · Stroke · 2003 · 1.3K citations · Full text
Medicine, Neurology, Neurosurgery +14
Heather J. Fullerton, Yvonne W. Wu, Shoujun Zhao et al. · Neurology · 2003 · 539 citations
Stroke in children and sickle-cell disease
Christopher J. Earley, Steven J. Kittner, B. R. Feeser et al. · Neurology · 1998 · 274 citations
Medicine, Neurology, Pediatrics +13
Risk factors for arterial ischemic stroke in childhood.
Fenella J. Kirkham, Alexandra M. Hogan · PubMed · 2004 · 50 citations
Medicine, Neurology, Pediatrics +16